Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Silo enters into commercial evaluation license agreement for next generation liposomes
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Subscribe To Our Newsletter & Stay Updated
